ÐÂÎÅ×ÊѶ
͸¹ýµ¥Ï¸°û¼¼ÊõµÄÀúÊ·Ñظ﷢ÏÖÔ¤ÅÐÖ×ÁöÃâÒßÖÎÁÆÁÙ´²½á¾ÖµÄÈ«ÐÂÊÖ¶Î
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÈðÈð
- À´Ô´£º
¡¾¸ÅÒªÃèÊö¡¿ÃâÒßÖÎÁÆÒѾÈò¿·ÖÄÑÖεÄÍíÆÚÖ×Áö»¼Õß»ñµÃÁËÁ¼ºÃµÄÔ¤ºóЧ¹û£¬µ«»¹Óд󲿷ֲ¡È˲¢Ã»ÓжÔanti-PD-1»òÕßanti-CTLA4µÈÃâÒßÖÎÁÆ×ö³öÓ¦´ð£¬³öÏÖÁËÃâÒßµÖ¿¹¡£
͸¹ýµ¥Ï¸°û¼¼ÊõµÄÀúÊ·Ñظ﷢ÏÖÔ¤ÅÐÖ×ÁöÃâÒßÖÎÁÆÁÙ´²½á¾ÖµÄÈ«ÐÂÊÖ¶Î
¡¾¸ÅÒªÃèÊö¡¿ÃâÒßÖÎÁÆÒѾÈò¿·ÖÄÑÖεÄÍíÆÚÖ×Áö»¼Õß»ñµÃÁËÁ¼ºÃµÄÔ¤ºóЧ¹û£¬µ«»¹Óд󲿷ֲ¡È˲¢Ã»ÓжÔanti-PD-1»òÕßanti-CTLA4µÈÃâÒßÖÎÁÆ×ö³öÓ¦´ð£¬³öÏÖÁËÃâÒßµÖ¿¹¡£
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÈðÈð
- À´Ô´£º
- ·¢²¼Ê±¼ä£º2022-05-16 13:27
- ·ÃÎÊÁ¿£º
ÃâÒßÖÎÁÆÒѾÈò¿·ÖÄÑÖεÄÍíÆÚÖ×Áö»¼Õß»ñµÃÁËÁ¼ºÃµÄÔ¤ºóЧ¹û£¬µ«»¹Óд󲿷ֲ¡È˲¢Ã»ÓжÔanti-PD-1»òÕßanti-CTLA4µÈÃâÒßÖÎÁÆ×ö³öÓ¦´ð£¬³öÏÖÁËÃâÒßµÖ¿¹¡£Òò´Ë¼ø¶¨Äܹ»Ô¤²âÄÄЩ²¡È˶ÔÃâÒßÖÎÁÆ×ö³öÓ¦´ð»òµÖ¿¹µÄ±êÖ¾Îï³ÉΪÁ˷dz£ÖØÒªµÄÒ»ÏîÈÎÎñ¡£Tϸ°ûÊÇ¿¹Ö×ÁöÃâÒß×îÖ÷ÒªµÄÊÊÓ¦ÐÔÃâÒßϵͳ£¬Ä¿Ç°´ó²¿·ÖÃâÒßÖÎÁƾ۽¹ÓÚTϸ°û£¬ÓÈÆäÊÇЧӦÐÔCD8+ Tϸ°û¡£Tϸ°ûÀàÐÍ¡¢±íÐÍ¡¢¹¦ÄÜЧӦ¼°±¾ÉíµÄ·Ö×Ó±í´ïÆ×£¨RNA¡¢µ°°×¡¢±í¹Ûµ÷¿ØµÈ£©ÒѾ±»¹ã·ºµÄÖ¤Ã÷¿ÉÒÔ×÷ΪԤ²âÃâÒßÖÎÁÆÓ¦´ð»òµÖ¿¹µÄÓÐÁ¦±êÖ¾Îï¡£
È»¶øÔÚÖ×Áö×éÖ¯ÄÚ£¬ºÜ¶àTϸ°û»á³öÏÖ¹¦ÄÜÕÏ°£¬Ê§È¥ÁËÏûÃðÖ×Áöϸ°ûµÄÄÜÁ¦¡£Óб¨µÀ·¢ÏÖÖ×Áö×éÖ¯ÄÚ½öÓÐ10%µÄCD8+ Tϸ°û¾ßÓÐʶ±ðÖ×Áöϸ°ûµÄÄÜÁ¦¡£ËäÈ»Ôö¼ÓµÄÃâÒßÇÖÈóÓëÃâÒßÖÎÁÆÏìÓ¦µÄÌá¸ß¾ßÓÐÏà¹ØÐÔ£¬µ«ÊÇÃâÒßÇÖÈóºÍÖ×Áö·´Ó¦ÐÔ²¢²»ÊÇÒ»Öµġ£Ö×ÁöÇÖÈóÁÜ°Íϸ°û£¨TILs£©ÖгýÁËÖ×Áö·´Ó¦ÐÔTϸ°û£¬»¹ÓÐÒ»Àà³ÆΪ“ÅÔ¹ÛÕß”µÄTϸ°û£¬ÕâÀàϸ°û²»ÄܶԿ¹ÔÆð·´Ó¦£¬²»»áÒýÆð¿¹Ö×ÁöЧ¹û¡£ÒÔÉÏÕâЩÒýÆðÁËÒ»¸ö·Ç³£ÖØÒªµÄÎÊÌ⣬µ½µ×ÄÄÒ»ÀàTϸ°û¾ßÓÐÖ×Áö·´Ó¦ÐÔ¡£¼ø¶¨ÕâÀà¾ßÓÐÖ×Áö·´Ó¦ÐÔµÄTϸ°ûÑÇȺ¶ÔÓÚÀí½â¿¹Ö×ÁöÃâÒß¡¢¿ª·¢ÐµÄÃâÒßÖÎÁƲßÂÔÊƱØÒâÒåÉîÔ¶¡£
¶àÏîÑо¿ÒѾ±¨µÀ·¢ÏÖÁ˽鵼ÃâÒßÖÎÁÆÏìÓ¦µÄTϸ°û²¢²»ÊÇÔ¤ÏÈ´æÔÚ×éÖ¯ÖеĺĽßÐÍTϸ°ûµÄÖØлָ´£¬¶øÊÇÓÉÍâÖÜÀ´Ô´µÄTϸ°ûËùÌæ´ú£¬·¢»Ó¿¹Ö×Áö×÷Óá£ÕâЩеĿË¡À©ÔöµÄÍâÖÜTϸ°ûͬÑù¿ÉÒÔ×÷ΪԤ²âÃâÒßÖÎÁƵıêÖ¾Îï¡£ÕâЩÑо¿¿ªÆôÁËÃâÒßÖÎÁƺó¶ÔѪҺTϸ°ûµÄÑо¿£¬´Ó¶ø¸üÒ×ÓÚ±êÖ¾ÎïµÄÁÙ´²×ª»¯¡£
| µ¥Ï¸°û¼¼ÊõÓëÃâÒßÖÎÁÆ
µ¥Ï¸°û¼¼ÊõÒѾ·¢ÏÖÁËÓëÃâÒßÖÎÁÆÏà¹ØµÄ¹Ø¼üϸ°ûÑÇȺ£¬°üÀ¨²»Í¬ÀàÐ͵ĶñÐÔϸ°ûºÍÃâÒßϸ°û¡£µ¥Ï¸°û¼¼Êõ½Ò¿ªÁËÖ×Áö΢»·¾³µÄÒìÖÊÐÔ£¬¼ø±ðÁ˺ܶàCD8+ Tϸ°ûÑÇÐÍÓëÃâÒßÖÎÁÆÓ¦´ð¾ßÓкÜÇ¿µÄÏà¹ØÐÔ¡£
Tϸ°ûÑÇÐÍ×÷ΪԤ²âÃâÒßÖÎÁÆÓ¦´ðµÄ±êÖ¾Îï
ÔÚµ¥Ï¸°ûÓ¦ÓÃÓÚÃâÒßÖÎÁÆÑо¿µÄÀúÊ·ÑظïÖУ¬ÔçÆÚ»ùÓÚ×éÖ¯ÃâÒß×黯µÄÑо¿Ö¤ÊµÁËÔÚanti-PD-1ÖÎÁƵÄÓ¦´ðºÚÉ«ËØÁö²¡È˵ÄÇÖÏ®Ö×Áö±ßÔµ£¬ ²»¹ÜÊÇÖÎÁÆÇ°»¹ÊÇÖÎÁƺóÏà¶ÔÓÚÎÞÓ¦´ðÕßCD8+ Tϸ°ûÔÚÓ¦´ð»¼ÕßÖеÄÔöÖ³»áÏÔÖøÔö¼Ó¡£ÏàÒ»Öµģ¬CD8+ Tϸ°ûµÄЧÄÜ·Ö×ÓGranzyme BÒ²ÔÚÓ¦´ð»¼ÕßÃâÒßÖÎÁƺóÏÔÖøÔö¼Ó[1]¡£
CD8\Ki67Ë«É«ÃâÒß×黯
| Á÷ʽ·ÖÎö
È»¶ø×éÖ¯Öмì²â²¢²»ÊÇÒ»¸ö×îÓŵıêÖ¾ÎïÑо¿·½°¸£¬2017ÄêWherryÍŶÓÔÚNature·¢ÎÄ·¢ÏÖÁ˺ÚÉ«ËØÁö²¡ÈËÍâÖÜѪÖÐÓëanti-PD-1»òÕßanti-CTLA-4ÖÎÁÆÏÔÖøÏà¹ØµÄTϸ°ûÑÇÐÍ[2]¡£ËûÃÇÀûÓøßά¶ÈµÄÁ÷ʽϸ°ûÊõ·¢ÏÖÁËÃâÒßÖÎÁƺóKi67+ PD-1+ CD8 Tϸ°ûÏÔÖøÔö¶à¡£µ«ÊÇËäÈ»ÖÎÁƺóÓдóÔ¼74%µÄ²¡ÈËÍâÖÜѪÖÐKi67+ PD-1+ CD8 Tϸ°ûÔö¼Ó£¬µ«ÊǽöÓÐ38%µÄ²¡ÈË»ñµÃÁÙ´²ÊÜÒ棬Òò´Ëµ¥¶ÀµÄKi67+ PD-1+ CD8 Tϸ°û²¢²»ÄÜÔ¤²âÃâÒßÖÎÁÆЧ¹û¡£ÕâÒ²°µÊ¾ÁË¿ÉÄÜ´æÔÚ¸üϸ·ÖµÄϸ°ûÑÇȺ»òÆäËûµÄÓ°ÏìÒòËØÓëÖÎÁÆЧ¹ûÏà¹Ø¡£Ñо¿ÕßÖ®ºó·¢ÏÖÁËKi67+ PD-1+ CD8 Tϸ°ûÓëÖ×Áö¸ººÉ£¨TB£©¾ßÓÐÏÔÖøµÄÏà¹ØÐÔ¡£Ki67µÄ¸ß±í´ïÒ²´ú±íןߵÄÖ×Áö¸ººÉ£¬Òò´ËKi67+ PD-1+ CD8 Tϸ°ûÔö¶à·´¶øԤʾ×ÅÔ¤ºó²»Á¼¡£×îÖÕÑо¿ÕßÌá³öÁËÀûÓÃKi67+ PD-1+ CD8 Tϸ°ûÓëÖ×Áö¸ººÉµÄ±ÈÖµ¿ÉÒÔÔ¤²â¶ÔÃâÒßÖÎÁƵÄЧ¹û£¬ÖÎÁƺóKi67/TB >1.94µÄ»¼Õß¾ßÓиߵÄ×ÜÌåÉú´æÂÊ¡£
Ô¤²âanti-PD-1ÖÎÁÆ
³ýÁËTϸ°ûµÄÀàÐͱ仯£¬Tϸ°ûµÄЧӦ·Ö×ÓͬÑùÓëÃâÒßÖÎÁƾßÓÐÏà¹ØÐÔ£¬¾ÍÏñÉÏÊöCD8+ Tϸ°ûµÄЧÄÜ·Ö×ÓGranzyme B¡£KriegµÈÀûÓÃÖÊÆ×Á÷ʽ£¨CyTOF£©ºÍFlowSOM·ÖÎöÁ˺ÚÉ«ËØÁö²¡ÈËÔÚanti-PD-1ÖÎÁÆÇ°ºóÍâÖÜѪPBMCÖеIJ»Í¬ÀàÐ͵Äϸ°û±ä»¯[3]¡£ËûÃÇ·¢ÏÖÁËÍâÖÜѪÖÐ×ܵÄCD4+ »òCD8+ Tϸ°ûµÄ±ÈÂÊÔÚÓ¦´ð»¼ÕßÖÐÏÔÖøϽµ£¬µ«ÊÇÀûÓÃCyTOF·ÖÎöTϸ°ûµÄ¶àÖÖ¹¦ÄÜϸ°ûÒò×Ó£¬·¢ÏÖÁËÿ¸öϸ°ûÒò×ÓÔÚÖÎÁÆÇ°ºóµÄ±ä»¯²»¾¡Ò»Ö£¬µ«ÊÇͨ¹ýÒò×Ó×éºÏÐԵķÖÎö·½·¨£¬Ñо¿Õß·¢ÏÖÁËCD4+ Tϸ°ûµÄ3ÖÖÀàÐ͵ÄÒò×Ó×éºÏÔÚÓ¦´ð»¼ÕßÖÐÏÔÖøÔö¼Ó£¬CD8+ Tϸ°ûÓÐ13ÖÖÀàÐ͵ÄÒò×Ó×éºÏÔÚÓ¦´ð»¼ÕßÖÐÏÔÖøÔö¼Ó¡£Õâ¸öÑо¿ËµÃ÷ÁËTϸ°ûµÄ¹¦ÄÜÐÔϸ°ûÒò×ÓÒ²¿ÉÒÔ×÷ΪԤ²âÃâÒßÖÎÁÆÊÇ·ñÓ¦´ð»òµÖ¿¹¡£
CD8+ Tϸ°ûµÄ²»Í¬Òò×Ó×éºÏ£¨CCG£©ÔÚÓ¦´ðºÍÎÞÓ¦´ð¼äµÄ²îÒì
| µ¥Ï¸°û²âÐò
Á÷ʽ·ÖÎöÒòÆäÓÐÏÞµÄmarkerÏÞÖÆÁËÐÂÀàÐÍϸ°ûÑÇÐ͵ķ¢ÏÖ£¬¶øµ¥Ï¸°ûת¼×é²âÐò£¨sc-RNA£©ÒÔÎÞÆ«µÄ¼ì²â·½Ê½½áºÏ¸÷Öָ߼¶µÄÉúÐÅ·ÖÎö·½·¨ÒѾ³ÉΪÁËÖ×ÁöÃâÒßÑо¿ÁìÓò×î³£Óõļ¼ÊõÊֶΡ£Sade-FeldmanµÈÈËÀûÓÃsc-RNA²âÐò·ÖÎöÁËתÒÆÐÔºÚÉ«ËØÁö»¼ÕßÔÚanti-PD1»òanti-CTLA4+PD1ÖÎÁÆÇ°ºó×éÖ¯ÖеÄÁÜ°Íϸ°û£¨CD45+£©[4]¡£¾Û½¹·ÖÎöCD8+ Tϸ°û£¬½á¹û¼ø±ðÁË2ÖÖÀàÐ͵ÄCD8+ Tϸ°û£¬ÆäÖÐÒ»Àà¸ß±í´ïTGF7»ùÒòµÄCD8+ Tϸ°ûÔÚÓ¦´ð»¼ÕßÖÐÏÔÖøÔö¼Ó£¬Í¨¹ýÃâÒßÓ«¹âÑéÖ¤ÁËTCF7+CD8+ Tϸ°ûÓëÃâÒßÖÎÁÆÓ¦´ð¾ßÓÐÏÔÖøÏà¹ØÐÔ£¬¿ÉÒÔ×÷ΪԤºó±êÖ¾Îͬʱ»¹·¢ÏÖÁ˱í´ïºÄ½ßÐÍmarker TIM3 ºÍCD39µÄCD8+ Tϸ°ûÔÚÎÞÓ¦´ð»¼ÕßÖÐÏÔÖø¸»¼¯¡£Í¬Ê±°ÐÏòÕâ2¸öºÄ½ßÐÍmarker¿ÉÒÔÔö¼Óanti-PD1µÄ¿¹Ö×ÁöЧ¹û¡£
sc-RNA²âÐò·¢ÏÖÔ¤²âÃâÒßÖÎÁÆÓ¦´ðµÄCD8+ Tϸ°ûÑÇÐÍ
| µ¥Ï¸°ûTCR²âÐò
³ýÁË֤ʵCD8+ Tϸ°ûÑÇÐÍ¿ÉÒÔÔ¤²âÃâÒßÖÎÁÆÓ¦´ð»òµÖ¿¹Í⣬ÁíÍâÒ»¸öÖØÒªµÄÎÊÌâÊÇÏìÓ¦ÃâÒßÖÎÁƵÄTϸ°ûÊÇÀ´Ô´ÓÚÔ¤ÏÈ´æÔÚµÄÖ×ÁöÇÖÈóÁÜ°Íϸ°û£¨TILs£©µÄÖØлָ´£¬»¹ÊÇÕ÷ļµÄеÄTϸ°û¡£2019ÄêÒ»ÏîNature medicineÉÏ·¢±íµÄÑо¿ÀûÓÃsc-RNA²âÐòºÍsc-TCR²âÐò·ÖÎöÁË11¸ö»ùµ×ϸ°û°©»¼Õßanti-PD1ÖÎÁÆÇ°ºóµÄTILs[5]¡£½á¹û·¢ÏÖÁ˺ĽßÐÍCD8+ Tϸ°ûÔÚÖÎÁƺó×îΪÏÔÖøÐÔµÄÔö¼Ó£¬ÕâЩºÄ½ßÐÍCD8+ Tϸ°û±í´ïÂýÐԻ¡¢Tϸ°û¹¦ÄÜÕÏ°ºÍÖ×Áö·´Ó¦ÐԵĻùÒò¡£½áºÏTCR²âÐò·¢ÏÖÁË¿Ë¡À©Ôö×î¶à»¹ÊǺĽßÐÍCD8+ Tϸ°û¡£È»¶ø¶Ô±È·ÖÎöÖÎÁÆÇ°ºÍÖÎÁƺóµÄTϸ°û¿Ë¡·¢ÏÖÁËÖÎÁƺó¾ø´ó²¿·ÖÀ©ÔöµÄ¿Ë¡ÔÚÖÎÁÆÇ°²¢²»´æÔÚ£¬ËµÃ÷ÁËÕâЩÀ©ÔöµÄ¿Ë¡ÊÇÔÚÖÎÁƺóÐÂÐγɵġ£Ñо¿Õß×îºó»¹½ÒʾÁËÖÎÁƺó´óÔ¼40%µÄTILs¿Ë¡¿ÉÒÔÔÚÍâÖÜѪÖмì²âµ½£¬²¢ÇÒÏÔÖøÔö¼ÓµÄÒ²ÊǺĽßÐÍCD8+ Tϸ°û¡£ËµÃ÷ÁË×éÖ¯ÖÐеÄTϸ°û¿Ë¡ºÜ¿ÉÄÜÊÇÀ´Ô´ÓÚÍâÖÜѪ¡£Ö®ºó2020ÄêNatureÉϵÄÒ»ÏîÑо¿Ö¤ÊµÁËÃâÒßÖÎÁƺóÖ×Áö×éÖ¯ºÍ°©ÅÔ×éÖ¯ÖдæÔÚ¹²Í¬¿Ë¡À©ÔöµÄTϸ°û£¬²¢ÇÒÔÚÍâÖÜѪÖÐҲͬÑù´æÔÚ[6]¡£
ÃâÒßÖÎÁƺóºÄ½ßÐÍCD8+ Tϸ°û¾ßÓÐ×î´óµÄ¿Ë¡À©Ôö£¬²¢ÇÒÊÇÓÉеĿË¡Ìæ´ú
ÄÇôÕâЩÍâÖÜѪÖпË¡À©ÔöµÄCD8+ Tϸ°ûÊÇ·ñÒ²ÓëÃâÒßÖÎÁÆÔ¤ºó¾ßÓÐÏÔÖøÏà¹ØÐÔÄØ¡£FairfaxµÈÈ˶Ô55¸öºÚÉ«ËØÁö²¡ÈËÔÚanti-PD1»òanti-PD1+CTLA4ÁªºÏÖÎÁÆÇ°ºóµÄѪҺCD8+ Tϸ°û½øÐÐÁ˳£¹æµÄת¼×éѧ·ÖÎö£¬Ö¤ÊµÁ˺ܶà±àÂëTCRµÄ»ùÒòÔÚÓ¦´ð×éÖеıí´ïÏÔÖø¸ßÓÚÎÞÓ¦´ðÕß[7]¡£²¢ÇÒÔÚÓ¦´ð»¼ÕßÖдæÔÚ¸ü¶àµÄ´óµÄCD8+ Tϸ°û¿Ë¡£¬´óµÄCD8+ Tϸ°û¿Ë¡Խ¶àµÄ»¼ÕßÔÚÖÎÁƺóµÄÉú´æÂÊÔ½¸ß¡£ËµÃ÷ÁËÍâÖÜѪÖпË¡À©ÔöµÄCD8+ Tϸ°û¿ÉÒÔ×÷ΪÃâÒßÖÎÁƵÄЧ¹ûµÄÔ¤²â±êÖ¾Îï¡£
ÍâÖÜѪÖпË¡À©ÔöµÄCD8+ Tϸ°û¿ÉÒÔÔ¤²âÃâÒßÖÎÁÆÓ¦´ðµÄ±êÖ¾Îï
¾ÍÏñÉÏÊöµÄһЩÑо¿ËùÊöCD8+ Tϸ°ûµÄ¹¦ÄÜЧӦÒò×ÓÒ²ÓëÃâÒßÖÎÁƵÄЧ¹û¾ßÓÐÏÔÖøÏà¹ØÐÔ¡£¹¦ÄÜÕÏ°µÄCD8+ Tϸ°ûÖ÷Òª¾ÍÊÇÒòΪ²»Äܹ»²úÉúЧӦÒò×Ó£¨ÀýÈçIFN-㣬TNF£©ºÍϸ°û¶¾·Ö×Ó£¨ÀýÈçgranzymes ºÍperforin£©£¬´Ó¶øʧȥÁËɱËÀÖ×Áöϸ°ûµÄÄÜÁ¦¡£Äܹ»¶ÔÃâÒßÖÎÁƺóÏìÓ¦£¬ËµÃ÷ÁËCD8+ Tϸ°û·ÖÃÚ¹¦ÄÜÐÔÒò×ÓµÄÄÜÁ¦Ôö¼Ó¡£Òò´Ë£¬ÕâЩ¹¦ÄÜÐÔϸ°ûÒò×ӵķÖÃÚ½áºÏTϸ°ûµÄ±ä»¯»òÐí¿ÉÒÔ¸üºÃµÄÔ¤²âÃâÒßÖÎÁÆÓ¦´ð»òµÖ¿¹¡£ÉÏÊöÓÐÏîÑо¿ÀûÓÃÖÊÆ×Á÷ʽ¼ì²âÁËϸ°ûÒò×Ó£¬µ«ÊÇÖÊÆ×Á÷ʽ¼ì²âµÄ±Ï¾¹²»ÊÇ»îϸ°û¶øÇÒ²»ÊÇÕæÕý·ÖÃÚ³öµÄϸ°ûÒò×Óº¬Á¿£¬ËùÒÔÐèÒª¸üºÏÊʵļ¼Êõ¼ì²âµ¥Ï¸°ûµÄ¹¦ÄÜÐÔµ°°×£¨Ï¸°ûÒò×Ó£©¡£ºÜ¶àÑо¿Í¨¹ýsc-RNA²âÐò½á¹ûÖÐÕâЩЧӦϸ°ûÒò×ӵıí´ïÍƲâCD8+ Tϸ°ûµÄ¹¦ÄÜ״̬£¬µ«ÊÇת¼ˮƽµÄ¸Ä±äºöÊÓÁ˵°°×ÐÞÊκÍÔÙ¼Ó¹¤µÄ¹ý³Ì£¬ÒѾÓÐÑо¿±¨¸æÁ˺ĽßÐÍCD8+ Tϸ°ûÓи߱í´ïmRNAµ«ÊǼ¸ºõ²»±í´ïµ°°×»òÕßϸ°û¶¾×÷Óã¬ËùÒÔ±ØÐë½÷É÷µÄÀûÓÃTϸ°ûת¼×éÊý¾ÝÍƲâÆ书ÄÜ״̬¡£ÈçºÎÍ»ÆƵ¥Ï¸°û¹¦Äܵ°°××éµÄÆ¿¾±£¬ÊµÏÖÕæÕýÒâÒåÉϵ¥Ï¸°û²ãÃæ·ÖÃÚµ°°××飨ϸ°ûÒò×Ó£©µÄ¼ì²â£¿È¥ÄêNat Rev Clin Oncol·¢±íµÄһƪ×ÛÊöÉÏÌáµ½ÁËÒ»Ïîеļ¼ÊõIsoPlexisµ¥Ï¸°û¹¦Äܵ°°××éѧ[8]£¬¿ÉÒÔͬʱ¼ì²â500-1500¸ö»îµÄµ¥Ï¸°û·ÖÃÚµÄ32ÖÖϸ°ûÒò×Ó£¬¶Ô¹Ø¼üϸ°ûÑÇÐͽøÐй¦ÄܱíÕ÷¡£
| IsoPlexisµ¥Ï¸°û¹¦Äܵ°°××é
2020Äê·¢±íÔÚJ Clin OncolÔÓÖ¾ÉϵÄÒ»ÏîÑо¿¾ÍÀûÓõ¥Ï¸°û¹¦Äܵ°°××éѧ·¢ÏÖÁËCD8+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔ¿ÉÒÔ×÷ΪNKTR-214£¨bempegaldesleukin£©ÓëOpdivo£¨nivolumab£©ÃâÒß×éºÏÁÆ·¨µÄÁÆЧԤ²â±êÖ¾Îï[9]¡£Ñо¿Õß·ÖÎöÁËѪҺCD8+ºÍCD4+ Tϸ°û¡¢NKϸ°û£¬Ö»Óж๦ÄÜÐÔCD8+ Tϸ°û£¨·ÖÃÚ≥2¸öÒò×Ó£©µÄ±ÈÀýÔڿ͹ۻº½âµÄ»¼ÕßÒ»×éÖÐÏÔÖøÉý¸ß£¬ÔÚÎÞÓ¦´ðµÄ»¼ÕßÖв¢Ã»Óб仯¡£ÕâÒ²ÓëÃâÒß¼ì²éµãÒÖÖÆÖ÷ÒªÓ°ÏìCD8+ Tϸ°ûµÄ½áÂÛÏàÒ»Ö¡£ÔÚÖ®ºóΪÆÚ3ÄêµÄÑо¿ÖУ¬Ñо¿Õß·¢ÏÖÁËCD8+ Tϸ°ûµÄ¶à¹¦ÄÜÖ¸ÊýPSI£¨¶à¹¦ÄÜÐÔϸ°û±ÈÀýx¼ì²âÒò×ÓµÄÐźÅÇ¿¶È£©²îÒì¸ßµÄ»¼Õß±íÏÖ³ö¸ü¸ßµÄ¿Í¹Û»º½âÂÊ¡£ÕâЩ½á¹û˵Ã÷ÁËͨ¹ýIsoplexisµ¥Ï¸°ûµ°°××é·ÖÎöµÃµ½µÄCD8+ Tϸ°û¶à¹¦ÄÜÐÔÖ¸ÊýPSI¿É³ÉΪÓ뻼ÕßÓ¦´ðÏà¹ØµÄÔ¤²âÐÔ±êÖ¾Îï¡£
CD8+ Tϸ°ûPSI²îÒì´óµÄµÄ»¼ÕßÃâÒßÖÎÁƺóµÄ¿Í¹Û»º½âÂʸß
ÍâÖÜѪÖÐCD8+ Tϸ°û¶à¹¦ÄÜÖ¸ÊýPSI»òÐíºÍTϸ°ûµÄ¿Ë¡À©ÔöÖ±½ÓÏà¹Ø¡£AxelrodµÈÈËÀûÓÃIsoPlexis·ÖÎöÁË4¸öÈéÏÙ°©²¡ÈËÔÚи¨Öú»¯ÁÆÇ°ºóÍâÖÜѪÖеÄPD1+ºÍPD1-µÄCD4¡¢CD8 Tϸ°û[10]¡£½á¹û·¢ÏÖÔÚÖÎÁƺóPD1+ CD8 Tϸ°ûµÄ¶à¹¦ÄÜÐÔÏÔÖøÔö¼Ó£¬Í¨¹ý¶ÔCD8 Tϸ°û½øÐÐTCR²âÐò·ÖÎö·¢ÏÖÖÎÁƺó¿Ë¡À©Ôö×î¶àµÄÒ²ÊÇPD1+ CD8 Tϸ°û£¬¶ø²»ÊÇPD1- CD8 Tϸ°û¡£Õâ¾Í˵Ã÷ÁËIsoPlexis·ÖÎöµÃµ½Tϸ°û¶à¹¦ÄÜÐÔÖ¸ÊýÓë¿Ë¡À©Ôö¾ßÓÐÖ±½ÓÏà¹ØÐÔ£¬ÊÇ·ñ¿ÉÒÔ·´Ó¦¿Ë¡À©ÔöµÄ³Ì¶È¿ÉÄÜÐèÒª¸ü¶àµÄÑо¿Êý¾ÝÀ´ÑéÖ¤¡£
и¨Öú»¯ÁÆÇ°ºóPD1+ CD8 Tϸ°û¿Ë¡ºÍ¶à¹¦ÄÜÐԵı仯
ËäÈ»ÃâÒßÖÎÁÆÖ÷Òª·¢»ÓЧӦµÄÊÇCD8+ Tϸ°û£¬µ«ÊÇÓÐÑо¿ÒѾ·¢ÏÖÁËCD4+ TÒ²¿ÉÒÔÖ§³ÖÃâÒßÖÎÁÆ·´Ó¦¡£AbbasµÈÈËÀûÓÃIsoPlexis·ÖÎöÁË16Ãû¼±ÐÔËèÑùÁÜ°ÍÁö»¼ÕßÔÚanti-PD1ÖÎÁÆÇ°ºó¹ÇËèÖеÄCD8+ºÍCD4+ Tϸ°û[11]¡£·¢ÏÖÁËÓ¦´ð»¼ÕßÖÐÖ»ÓÐCD4+ Tϸ°ûµÄ¶à¹¦ÄÜÖ¸ÊýPSIÏÔÖøÔö¼Ó£¬Óë×ÜÉú´æÂʾßÓÐÏÔÖøÏà¹ØÐÔ¡£Ã¿¸öÒò×ӵűÏ׶ȷÖÎö½ÒʾÁËIFN-γºÍTNF-αÊÇÇý¶¯CD4+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔÔö¼ÓµÄÖ÷ÒªÇý¶¯Òò×Ó¡£¾ÛÀà·ÖÎöÒ²½ÒʾЧӦÐÔÒò×ÓÔÚÓ¦´ð»¼ÕßCD4+ Tϸ°û·ÖÃÚµÄÒò×ÓÖÐÕ¼Ö÷µ¼¡£
CD4+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔ·¢ÉúÁ˸ıä
½üÆÚJ Immunother CancerÔÓÖÊ·¢±íµÄÒ»ÏîÁÙ´²2ÆÚÊÔÑéÖУ¬Í¬ÑùÀûÓÃIsoPlexis·ÖÎö·¢ÏÖÁËѪҺÖÐCD4+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔÓëÃâÒßÖÎÁƾßÓÐÏÔÖøÏà¹ØÐÔ[12]¡£ÕâÏîÊÔÑéÊÇÁÙ´²×ª»¯±êÖ¾ÎïµÄÑо¿£¬Ä¿µÄÊÇΪÁËÔ¤²âanti-CTLA4»òÕßÁªºÏanti-PD1ÖÎÁÆÍíÆÚºÚÉ«ËØÁö²¡È˵ÄÓ¦´ð¡£Ê×ÏÈÊÇͨ¹ýCyTOF·¢ÏÖÁËÓ¦´ð»¼ÕßÖÐCD4+ Tϸ°ûÔÚÖÎÁƺóÏÔÖøÔö¼Ó£¬²¢ÇÒÖ÷ÒªÊÇÖÐÑë¼ÇÒäÐÔTϸ°ûµÄÔö¼Ó£¬²»Êǵ÷½ÚÐÔTϸ°û¡£Ö®ºóIsoPlexis½øÐй¦ÄܱíÕ÷·ÖÎö£¬Ò»Öµģ¬CD4+ Tϸ°ûµÄPSIÔÚÖÎÁƺóÏÔÖøÔö¼Ó£¬²¢ÇÒÖ÷ÒªÊÇЧӦÐÔÒò×ÓµÄÔö¼Ó£¬µ÷½ÚÐÔÒò×Ó·´¶øÔÚÓ¦´ð»¼ÕßÖÐÊÇϽµµÄ£¬ÕâÒ²ÓëCyTOFµÄ½á¹ûÏàÒ»Ö¡£
CyTOFºÍIsoPlexisÁªºÏ·ÖÎö·¢ÏÖCD4+ Tϸ°û¶à¹¦ÄÜÐÔÔÚÃâÒßÖÎÁƺóÏÔÖøÔö¼Ó
¶ÔÓÚ°ÐÏòÃâÒßÒÖÖƼì²éµãÖÎÁƵֿ¹µÄ²¡ÈË£¬¿ÉÒÔ²ÉÓÃTILµÄ¹ý¼Ìϸ°ûÁÆ·¨¡£Nature medicineÉÏ·¢±íÁËÒ»ÏîÁÙ´²1ÆÚÊÔÑ飬ÆÀ¹ÀÁËTIL ¹ý¼Ìϸ°ûÁÆ·¨´¦Àíanti-PD1ÖÎÁƺ󼲲¡»¹½øÕ¹µÄ²¡ÈË[13]¡£»îÐÔÆÀ¹À·¢ÏÖÁË69%£¨11/16£©µÄ²¡ÈË·¢ÉúÁËÖ×ÁöÏûÍË¡£ÎªÁËÆÀ¹ÀTIL ¹ý¼Ìϸ°ûÁÆ·¨¶ÔÌåÄÚTϸ°û¹¦ÄܵÄÓ°Ï죬Ñо¿ÕßÀûÓÃIsoPlexis·ÖÎöÁËÆäÖÐ12Ãû»¼ÕßÓÃÒ©½ø³Ì²»Í¬½×¶ÎѪҺÖÐCD8+ºÍCD4+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔ¡£½á¹û·¢ÏÖÁËTIL ¹ý¼Ìϸ°ûÁÆ·¨Ö÷ÒªÊÇÔö¼ÓCD8+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔ¡£Í¬ÑùµÄ£¬Á÷ʽϸ°ûÊõ·ÖÎöҲչʾÁËTIL ¹ý¼Ìϸ°ûÁÆ·¨Ö÷ÒªÔö¼ÓµÄÊÇЧӦÐÔCD8+ Tϸ°û¡£Õâ˵Ã÷ÁËIsoPlexis·ÖÎöµÃµ½µÄ¶à¹¦ÄÜÐÔÖ¸ÊýPSIÓëϸ°û±íÐÍÏàÒ»Ö¡£
TIL ¹ý¼Ìϸ°ûÁÆ·¨Ö÷Òª³ÖÐøÔö¼ÓCD8+ Tϸ°ûµÄ¶à¹¦ÄÜÐÔ
ÔÚÆÀ¹ÀÃâÒßϸ°ûÓëÖ×ÁöÃâÒßÖÎÁƼäµÄÏà¹ØÐÔÉÏ£¬Ñо¿µÄÇ÷ÊÆÒѾ´Ó½ö½öµÄϸ°û±íÐÍÌØÕ÷¹ØÁªÏòϸ°û¹¦ÄÜÌØÕ÷¹ØÁª·¢Õ¹¡£IsoPlexisµ¥Ï¸°û¹¦Äܵ°°××éѧ¿ÉÒÔͬʱʵÏÖ¶Ô500-1500µ¥¸öϸ°û·ÖÃÚµÄ32ÖÖ¹¦Äܵ°°×µÄ¼ì²â£¬ÆäÌṩµÄµ°°×ÖÊ×éѧ¹¦ÄܲãÃæµÄÊý¾Ý£¬ÓëÁÙ´²½á¹û¾ßÓÐÏÔÖøÏà¹ØÐÔ¡£ÌرðÊÇÔÚÖ×ÁöÃâÒßÁìÓò£¬¶ÔTϸ°û¹¦ÄܱíÕ÷Ñо¿¾ßÓиïÃüÐԵĸı䡣
| Ïà¹ØÎÄÏ×
1. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71.
2. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60-65.
3. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144-153.
4. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175(4):998-1013.e20.
5. Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251-1259.
6. Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020;579(7798):274-278.
7. Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H et al. Peripheral CD8 + T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat Med. 2020;26(2):193-199.
8. Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(4):244-256.
9. Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma et al. J Clin Oncol. 2021;39(26):2914-2925.
10. Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ et al. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clin Cancer Res. 2020;26(21):5668-5681.
11. Abbas HA, Sun H, Pierce SR, Kanagal-Shamanna R, Li Z, Yilmaz M et al. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv. 2022 Apr:bloodadvances.2022007172.
12. Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas Aet al. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer. 2022;10(1):e003853.
13. Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410-1418.
µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã
µç»°£º400-869-2936£¬021-33968791
ÓÊÏ䣺support@wayenbiotech.com
´«Õ棺021-33938792
QQ£º2120485725
Õ½ÂÔºÏ×÷
Õ½ÂÔºÏ×÷
| Full Moon | RayBiotech | CDI | IZON | Bio-Rad | R&D Systems | IsoPlexis | ÄÏÄ£ÉúÎï | Å·Ò×ÉúÎï | ÆäÃ÷ÐÅÏ¢ | ÃÀ¼ªÉúÎï | ÂóÌØ»æÆ× |
Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿·¢(Öйú)Ô´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£